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Abstract
Neural crest (NC) cells are a multipotent stem cell population that gives rise to a
diverse array of cell types in the body, including peripheral neurons, Schwann cells
(SC), craniofacial cartilage and bone, smooth muscle cells, and melanocytes. NC for-
mation and differentiation into specific lineages takes place in response to a set of
highly regulated signaling and transcriptional events within the neural plate border.
Pre-migratory NC cells initially are contained within the dorsal neural tube from
which they subsequently emigrate, migrating to often distant sites in the periphery.
Following their migration and differentiation, some NC-like cells persist in adult tis-
sues in a nascent multipotent state, making them potential candidates for autologous
cell therapy. This review discusses the gene regulatory network responsible for NC
development and maintenance of multipotency. We summarize the genes and signal-
ing pathways that have been implicated in the differentiation of a post-migratory NC
into mature myelinating SC. We elaborate on the signals and transcription factors
involved in the acquisition of immature SC fate, axonal sorting of unmyelinated neu-
ronal axons, and finally the path toward mature myelinating SC, which envelope
axons within myelin sheaths, facilitating electrical signal propagation. The gene regu-
latory events guiding development of SC in-vivo provides insights into means for dif-
ferentiating NC-like cells from adult human tissues into functional SC, which have
the potential to provide autologous cell sources for the treatment of demyelinating
and neurodegenerative disorders.
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1 | INTRODUCTION TO THE NEURAL
CREST CELLS
Often referred to as the “fourth germ layer,” the neural crest (NC) is a
multipotent and migratory stem cell population that contributes to a
wide array of organs and tissues in the vertebrate embryo, including
autonomic ganglia, sensory neurons, adrenal and thyroid glands, carti-
lage and bone of the face, smooth muscle cells of some major arteries,
and melanocytes in the skin.1,2 NC formation is first observed at stage
9 of human embryogenesis and extends till stage 20 as per the Carne-
gie staging system.3 Neural crest stem cells (NCSC) were first identi-
fied in rodents by Stemple and Anderson and isolated using cell
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sorting for NC-specific cell surface protein p75NTR (neurotrophin
receptor [NTR]). These p75NTR+ cells could self-renew and generate
neurons and glia of the PNS as well as myofibroblasts.4 The high
degree of self-renewal and regenerative capacity of NC makes it a
very attractive source for stem cell-based therapies.
During embryonic development, formation of NC stem cells origi-
nates in response to a set of signaling events between neural and non-
neural ectoderm, a region termed as the neural plate border.5 Induction
is initiated at the plate border by signals including fibroblast growth fac-
tor (FGF), bone morphogenetic protein (BMP), andWnt.5,6 On establish-
ment of the neural plate border territory, new signaling events are
established for specification of bona fide NCSCs. This process results in
expression of NC specifiers (Snail2, Sox8, Sox9, Sox10, FoxD3, c-Myc,
and Id family members) that in turn mediate changes in shape, motility,
and adhesive properties leading to delamination of NCSCs from the neu-
roepithelium and initiating cell lineage decisions.6 NC precursor cells
within the dorsal neural tube then undergo epithelial to mesenchymal
transition and migrate along precise pathways,7 eventually settling and
differentiating into specialized cell types, according to their axial origin as
well as environmental cues encountered during the process.8 Cranial
NCSCs form craniofacial structures of the head including cartilage and
bone tissue of the skull and face, as well as cranial neurons, glia, and con-
nective tissue of the face. Trunk NCSCs differentiate into dorsal root
ganglia (DRG), containing sensory neurons and satellite glial cells, endo-
crine cells of the adrenal glands, and Schwann cells (SC) along the spinal
nerves. Some of these NCSCs also differentiate into melanocytes in the
skin. Finally, vagal NCSCs populate the enteric nervous system (ENS)
along the length of the gut and contribute to the connective tissues of
the arteries, septation of the outflow tract and cardiac ganglion.1
2 | SOURCES OF NC-LIKE STEM CELLS IN
ADULT TISSUES
2.1 | NC characteristics are retained
post-embryonically in adult tissues
Although NC cells are often referred to as stem or stem-like cells, they
are a transient population in the embryo that becomes progressively
restricted in developmental potential during the course of develop-
ment and rapidly lose their multipotency. Nevertheless, recent evi-
dence suggests that many NC derivatives, including skin, cornea, gut,
and peripheral nerves, contain stem or precursor cells with the ability
to give rise to multiple NC derivatives.1,9 These tissues provide poten-
tial sources for obtaining multipotent neural crest-like stem cells
(NClSCs) for the purpose of regenerative medicine and cell therapy,
and consequently, they are under study in several laboratories.
Whether NC-like cells from the adult tissue come from embryonic
NCs and remain dormant in a multipotent state or they attain a spe-
cialized fate and dedifferentiate to their NC progeny in specific cul-
ture conditions has not been established yet. The answers to these
questions can only be attained by lineage-tracing experiments track-
ing migration and differentiation of NCs starting from embryo devel-
opment and throughout adulthood.
NClSCs have been isolated from mouse bone marrow and DRG.
Nagoshi et al used double-transgenic mouse strains P0 and Wnt1-Cre/
Floxed-EGFP to map and isolate NClSCs from bone marrow, DRG, and
whisker pad using cell-sorting. P0 andWnt1 are marker genes expressed
inNC cells in mouse embryos.10 Interestingly, DRG-derivedNClSCs gen-
erated more primary and secondary spheres compared with bone mar-
row and whisker pad–derived cells and showed increased expression of
NCmarkers p75NTR, Sox10, Nestin, andMusashi1. Additionally, 75% of
DRG-derived spheres showed tri-lineage differentiation to neurons, glia,
and myofibroblasts, compared with only 7.3% of spheres derived from
whisker pad and 3.3% in spheres derived from bone marrow.10 These
results highlight the tissue-dependent differences in the abundance and
self-renewal capacity of adult NClSCs, which may ultimately determine
the suitability for cellular therapies. Furthermore, bone marrow–derived
NCs could be differentiated into SC that showed myelination around
DRG neuronal axons in vitro, indicating their potential for use in periph-
eral nerve regeneration.11
During development, NCs also migrate to the cornea, where their
derivatives remain throughout adulthood. The cornea is a transparent
avascular structure that covers the front of the eye and helps to focus
light on the retina. The cornea consists of three major cellular compo-
nents: a stratified epithelium, a collagenous stroma containing ker-
atocytes, and a layer of endothelium.1 Experiments with chick-quail
chimeras demonstrated that cranial NC cells form the corneal endo-
thelium and keratocytes.12–15 Lineage tracing experiments demon-
strated that upon transplantation from late into early chick embryos
quail NC-derived keratocytes followed normal migratory routes giving
rise to smooth muscle cells, myofibrils, keratocytes, and endothelial
cells but failed to differentiate into neurons or cartilage, suggesting
restricted plasticity of these NC-derived progenitors.16 Another study
however demonstrated differentiation of corneal progenitor cells into
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keratocytes, fibroblasts, myofibroblasts, adipocytes, chondrocytes,
and neural cells, indicating similar differentiation potential to NCSC.17
Stem cell derivatives of NC origin persist in the adult rodent gut
from which they can be isolated based on CD49b expression. Sorted
cells showed expression of NC marker genes, such as p75NTR, Sox10,
and Nestin, along with markers specific to enteric glia such as S100B
and glial fibrillary acidic protein.18 Multipotent progenitors from fetal
gut exhibited more plasticity and degree of self-renewal compared
with those derived from adult gut. In addition, upon transplantation
into chick embryos, fetal progenitors gave rise primarily to neurons,
whereas postnatal gut progenitors turned predominantly into glia.19
In vivo grafting experiments suggest therapeutic potential of these
progenitors for the treatment of ENS disorders.20,21
Cardiac NC cells play a role in septation of cardiac outflow tract into
pulmonary and aortic branches.1 In vitro clonal expansion of NCISCs iso-
lated from cardiac tissue suggested that only a small fraction of them
were capable of self-renewal and generation of NC derivatives.22 Stem
cells from neonatal rodent heart demonstrate a “NC-like” behavior, and
when grown as cardiospheres, they could differentiate into PNS neu-
rons, glia, smooth muscle cells, and cardiomyocytes, as well as migrate to
tissues characteristic for NC derivatives in ovo.23 Interestingly, cardiac
resident Nestin+ progenitors migrated to areas damaged by infarction
and contributed to reparative vascularization, indicating their potential
for the treatment of various heart diseases.24
Although the presence of NClSCs in developed tissues provides
evidence of an alternative cell source for cell therapy, most studies of
this type have been limited to rodents, due to inaccessibility of human
NCs in organs such as gut, heart, DRG and spine, as shown in
Figure S1. Interestingly though, NCISCs have also been isolated from
adult human tissues such as skin and dental pulp. The isolation of
NClSCs from skin tissue enhances their therapeutic potential, mostly
because of the accessibility and size of skin tissue that can provide
autologous cells for cell therapies.25–28 Fernandes et al showed that
endogenous adult dermal precursors residing in the papillae of hair
and whisker follicles could give rise to multipotent NClSCs.25 Similarly,
Sieber-Blum et al reported the presence of multipotent NCISCs in the
adult mammalian hair follicle, which could give rise to neurons, mela-
nocytes, smooth muscle cells, SC, and chondrocytes in vitro. These
multipotent cells were termed epidermal neural-crest cells,26 and
when grafted in a mouse model of SCI, they integrated into the host
spinal tissue yielding improvements in touch perception and sensory
connectivity.29
2.2 | Multipotent NClSCs from interfollicular
epidermis
Recently, in our laboratory, Bajpai et al devised a method to reprogram
postnatal human epidermal keratinocytes (KCs) to NClSC (termed KC-
NC) by mimicking signaling events that occur at the neural plate border.
Transcriptomic analysis confirmed that epidermally derived NCISCs
were similar to those generated from human embryonic stem cells (ESCs)
and maintained the multilineage differentiation potential into melano-
cytes, neurons, SC, and mesenchymal cells in vitro and in ovo.30 In a
subsequent study, we identified the factors that promote expansion of
KC-NC and maintain the NC phenotype. Specifically, we showed that
FGF2 was necessary and sufficient for expression of Sox10, but both
FGF2 and IGF1 worked synergistically to upregulate FoxD3. In addition,
inhibition of TGF-β1 further enhanced Sox10 expression.31 We also
demonstrated that the same signaling factors can be used to obtain
multipotent and functional NClSCs from cultures of human inter-
follicular KC isolated from elderly donors.32 Interestingly, NClSC from
older donors exhibited significantly younger epigenetic age than epider-
mal KC, perhaps indicating greater potential for cell therapies. Given the
accessibility, high proliferative capacity, and ease of reprogramming
without genetic modification, KC-NC represent an abundant, autologous
source of functional therapeutic cells for regenerative medicine. They
can also provide an excellent culture system for studying human disease,
similar to induced pluripotent stem cells (iPSCs) but without the need for
geneticmodification or reprogramming to the pluripotent state.
2.3 | Schwann cell precursors contribute to NC
derivatives
Recent evidence suggests that NC cells that become associated with
peripheral nerves acquire a partial glial phenotype, assuming the charac-
teristics of a “Schwann cell precursor” (SCP). Intriguingly, it has been
shown that late embryonic stages, many melanocytes originate from
nerve-associated SCPs.33 This occurs well after NC cells destined to form
melanocytes have emigrated from the neural tube. Similarly, lineage anal-
ysis in mice has shown that cranial parasympathetic ganglia as well as a
subpopulation of enteric neurons arise from this cell population.34–36
This is consistent with the possibility that later NC derivatives may arise
from an SCP population that represents a nascent stem cell population
associated with peripheral nerves. These SCPs express characteristic
marker genes that are different from those expressed by migratory
NCSC but similar to markers expressed by immature SC. For example,
SCPs express genes encoding myelin basic protein (MBP), peripheral
myelin protein 22 (PMP22), desert hedgehog, Cadherin 19, Connexin
29, GAP43, BFABP, and other Schwann cell markers, many of which are
also associated with differentiation into myelinating SC.37–41 However,
rather than being restricted to differentiate into SC, SCPs remain
multipotent and appear to have the ability to contribute to numerous lin-
eages at much later times in embryogenesis than normally associated
with NC migration. In fact, recent studies also suggest that SCPs may
give rise to chromaffin cells of the adrenal medulla, as evidenced by sin-
gle cell RNA sequencing (scRNA-seq) of the developing adrenomedullary
cells in mice.42 This raises the intriguing possibility that these may repre-
sent true stem cells with remarkable multipotency and regenerative
ability.
The transition frommigratory NC cell to SCPs likely occurs when NC
cells approach and/or become associated with peripheral nerves ema-
nating from sensory and autonomic ganglia. At this point, the NC-derived
cells upregulate genes typically associated with SC while downregulating
more typical NC markers, thus assuming a more glial like state.38,43
Although these cells may be biased toward glial lineages, they remain
multipotent and we speculate that perhaps they “dedifferentiate” similar
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and give rise to other NC fates similar to radial glia which are neuronal
progenitors in the central nervous system. Whether SCPs maintain their
multipotency into adulthood and the full range of cell types into which
they can differentiate remain open questions.
3 | GENE REGULATION IN NC CELLS: FATE
ACQUISITION AND MULTIPOTENCY
MAINTENANCE
3.1 | An NC gene regulatory network controls
lineage diversification into neuronal, melanocytic, and
glial, including Schwann cell lineages
The NC is an excellent model system for studying questions of stem
cell biology due to its multipotency, motility, and ability to form a
broad array of derivatives. These are as diverse as neurons and SC of
the peripheral nervous system, craniofacial cartilage, and bone, as well
as skin melanocytes. These inherent stem cell properties have poten-
tially important implications in regenerative medicine to treat disor-
ders like familial dysautonomia, cleft palate, and NC-related heart
conditions such as Persistent Truncus Arteriosus, as well as to under-
stand anomalies in differentiation that lead to cancers such as melano-
mas and Schwannomas.
The recent expansion of molecular biological techniques including
single-cell RNA-seq, ChIP-seq, and ATAC-seq have facilitated the dis-
section of the genetic program controlling NC development. These
genomic approaches have provided important insights into gene regu-
latory mechanisms and uncovered new regulatory factors involved in
control of NC formation and diversification.44,45 It is now clear that an
intricate array of transcription factors and signaling molecules act in
concert to imbue NC cells with its broad multipotency and migratory
ability. These factors have been proposed to act via a multistep NC
gene regulatory network (GRN) that integrates transcriptional inputs
and diverse environmental signals.2,5,46,47 The NC GRN consists of a
series of hierarchically arranged regulatory steps including induction
of the prospective NC at the neural plate border; specification of
multipotent NC cells within the dorsal neural tube; control of their
delamination via an epithelial to mesenchymal transition to produce a
migratory population; and finally, diversification into distinct cell
lineages.
The NC GRN posits that the process of NC formation is comprised
of a logical series of distinct regulatory steps that flow seamlessly
from one to the other. First, signaling molecules including Wnts, FGFs,
and BMPs in the gastrula stage embryo initiate the process of NC
induction by inducing transcription factors like Msx, Pax3/7, Zic1, and
Dlx3/5 at the border between the neural plate and nonneural ecto-
derm. The region where these genes are coexpressed defines the neu-
ral plate border—a domain primed to form bona fide NC cells. These
in turn function in combination with signaling molecules to regulate
“NC specifier genes” like Snail/Slug, AP-2, FoxD3, Twist, Id, cMyc, and
Sox8/9/10. The NC GRN itself can be envisioned as a series of
sequential binary decisions leading to differentiation into derivative
fates. Recently Twist1 has been reported to play a critical role as a
regulator of NC fate decision, and it biases NC commitment toward a
mesenchymal fate.45 Conversely, FoxD3 represses the mesenchymal
program of delaminating NCs.48 The postmigratory program begins
following the downregulation of transcription factors associated with
the neural tube program such as Zic3 and Pax8.
Expression of the Sox family genes initiates within the dorsal neu-
ral tube and defines cells with the potential to emigrate from the neu-
ral tube and form migratory NC cells. In particular, the SoxE
transcription factors (Sox8/9/10) are critical regulators of most NC
lineages.5,49,50 Specifically, Sox8 and Sox9 are expressed early in the
newly induced NC, preceding Sox10, which serves as a nearly pan
migratory NC marker. At later developmental stages, Sox9 and Sox10
persist in specific NC subpopulations. Whereas Sox9 is maintained in
NC-derived chondrocytes, Sox10 persists in neuronal, glial, and mela-
nocyte lineages and controls their specification in combination with
different cofactors in each lineage.
Sox10 regulates differentiation of sensory and autonomic lineages
by regulating expression of achaete-scute homolog 1 and the paired
homeodomain (Phox2b) transcription factors that are essential for
neurogenesis in the autonomic lineage.51 In the DRG, transient
expression of Sox10 regulates expression of neurogenin.52 Sox10 also
binds to endothelin receptor-B (EDNRB) to regulate development of
the ENS, and disruption in this binding has been shown to cause
Hirschsprung disease.53 Sox10 also is critical for emergence of the
glial lineage by regulating Oct6 and Krox20 (Egr2) transcription fac-
tors, which are critical for myelination.54–56 Its expression persists
through subsequent stages of terminal differentiation,49 regulating
expression of myelin proteins, including protein zero (P0)57, MBP,
PMP22, and the gap junction protein connexin 32.58
3.2 | Diverse signaling pathways govern NC cell fate
during embryogenesis
Many studies have focused on discovering the regulatory pathways
that control NC fate acquisition in order to better understand cell fate
specification during embryonic development in vivo and develop
bioinspired strategies to differentiate NC into different lineages
in vitro.
After formation of the neural tube, NC cells separate from the
neuroepithelium and migrate to distant anatomic locations, while mak-
ing cell lineage decisions in response to multiple morphogenetic sig-
nals.59,60 However, some NCs remain unspecified and retain their
stemness and multipotency.9,61 In general, there is significant hetero-
geneity with respect to the differentiation capacity of NCs, with some
giving rise to multiple derivatives while others differentiating into a
subset of cell types,62,63 depending on anatomic location and the
presence of fate specifying signals. NCs from all axial levels give rise
to neurons, glia, and pigment cells, but mesenchymal cell specification
depends on axial position. Cranial NCs give rise to skeletal mesen-
chyme; trunk NCs give rise to dorsal fin mesenchyme in amphibians
and fish; and vagal NCs contribute to smooth muscle cells of the car-
diac outflow tract.64,65
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One of the earliest NC markers includes the family of receptor
tyrosine kinases (RTK), which plays an important role in cell migration
and survival. The RTK family are critical for development of NC deriv-
atives in vivo.66 At migratory stages, the neurotrophin factor NT-3
binds to the trkC receptor and induces sensory neurogenesis.67 GDNF
binds to the RET receptor during ENS development.66 Neuregulin
binds to receptor ErbB3 and is required for glia formation in the
peripheral nervous system.68 Binding of steel factor to the c-kit recep-
tor promotes formation of melanocyte precursors,60 whereas cartilage
precursors express platelet-derived growth factor receptor α.69
The timing of NCmigration during development also affects the fate
they attain as cell specific genes are expressed at different times during
migration. Early-migrating cells express transcription factors Brn3 or
neurogenin-2 and commit to sensory neuron lineage.70,71 Late-migrating
cells express melanocytic-specific markers in the migration staging area
after departure of the early-migrating NCs.72 These signals contribute to
themolecular heterogeneity of the premigratoryNCs.
Three main classes of signals, namely Wnts, BMP2/4, and
TGFβ1/2/3, influence NC cell fate during and following migration
(Figure 1).73,74 Their interplay, timing, and relative intensity determine
the proportion of various derivatives generated during development.
Wnts and the downstream β-catenin pathway have been found to pro-
mote pigment cell formation in zebrafish embryo, possibly through acti-
vation of Nacre (Mitfa), a gene necessary and sufficient for pigment cell
formation; conversely, inhibition of Wnt signaling leads to generation of
neurons at the expense of pigment cells.75,76 Conditional deletion of
β-catenin inmice prevented sensory ganglion formation, whereas consti-
tutive activation led to formation of sensory neurons at the expense of
other NC derivatives.77,78 The second class of signaling molecules,
BMP2/4 are known to induce autonomic neurogenesis via expression of
Ascl1 (MASH1), a basic helix-loop-helix transcription factor expressed in
autonomic neuron precursors prior to differentiation. Interestingly, con-
tinuous BMP signaling is required for commitment of NCs to neuronal
fate.79 Although BMP2/4 have been identified as factors promoting
specification of NCs to an autonomic lineage, it does not prevent sensory
neurogenesis in NCs prespecified to a sensory fate in vivo.70
The members of TGFβ superfamily—1/2/3 are also able to specify
NC cell fates, through a different mechanism than BMP2/4, since they
signal through a separate receptor complex and have different down-
stream effectors.75 TGFβ1/2/3 were shown to promote cardiac smooth
muscle specification of rat NCs, as evidenced by the expression of
smooth muscle actin.74 TGFβ1/2/3 are also expressed in the developing
heart and thought to be active during the induction of cardiomyogenesis
inNCs, as well as at final stages of cardiac cushion tissue formation.80
The development of SC from NCs results from exposure of NCs to
neuregulin-1 (NRG1, also known as Glial Growth Factor), an inductive
signal of the neuregulin family. NRG1 has been found to suppress neuro-
nal differentiation and specify NCs to a Schwann cell fate.81 Themolecu-
lar mechanisms governing differentiation of NCs to SC are elaborated
later in this review. The interplay of signaling pathways and their effect
on different transcription factors are summarized in Figure 1.
4 | MOLECULAR MECHANISMS
UNDERLYING DIFFERENTIATION OF NC
CELLS TO SC
During development, NCSC) delaminate from the neural tube and
translocate to various regions of the embryo. Some localize adjacent
to the developing nerves, where they differentiate into SCPs, which in
turn give rise to a variety of peripheral glial cells that ultimately
F IGURE 1 Role of Sox10 in differentiation to neural crest (NC)-specific lineages. Sox10 is required for differentiation of NCs to neurons,
melanocytes, and Schwann cells, but downregulated for smooth muscle cell differentiation. Red arrows represent direct binding sites of Sox10 to
lineage specific transcription factors. Dashed red lines indicate no evidence for direct binding of Sox10. Green boxes represent extrinsic signals
during differentiation. Factors that act synergistically with Sox10 are depicted in blue clouds. Downstream targets of gene regulation by Sox10
are depicted in pink boxes
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perform a plethora of functions linked to myelination, neuronal sup-
port, regulation of synaptic connectivity and sensory function. ErbB3/
Nrg1 interactions and the transcription factor Zeb2 are involved in lin-
eage specification and myelination82–84; however, the precise mecha-
nisms dictating the fate acquisition from NC to SCP and mature
myelinating or nonmyelinating SC, as well as the role of metabolic
pathways in SC development and myelination, are not yet completely
understood.
4.1 | The role of Sox10, Pax3, and HDAC1 in NC
lineage specification to SCP
The transcription factors Sox10 and Pax3 are responsible for mainte-
nance of NC multipotency and for differentiation into SC and melano-
cytes. Although Sox10 is an important NC specifier,85 it is not the sole
transcription factor setting the lineage specification and differentia-
tion mechanisms in motion. Peripheral glial lineage specification is
abolished when HDAC1/2 knockout mice (flanked by LoxP)86 are
crossed with mice expressing Cre recombinase (Cre) under the control
of Wnt1 promoter (Wnt1-Cre).87,88 Furthermore, HDAC1/2 has been
shown to interact with Sox10 and activate two promoters,89,90 the
early lineage marker Myelin Protein Zero (MPZ or P0)61 and Pax3. In
turn, a positive feedback loop is set in motion, where Pax3 and Sox10
activate the Sox10 MCS4 enhancer, to maintain high levels of Sox10
but also upregulate expression of Fabp7, another early SCP
marker.90,91 Interestingly, Sox10 expression precedes neuronal differ-
entiation92,93 but is downregulated during neurogenesis. In addition
to Sox10 and Pax3, another key transcription factor FoxD3 plays a
key role in glial fate acquisition, by biasing migrating NC against alter-
native melanocytic fate.94–96 Considering that Sox10 is also necessary
for melanocytic differentiation and survival, the combined action of
Sox10 and FoxD3 is necessary for commitment of NC to peripheral
glial fate acquisition.
4.2 | Path to myelination—Signaling during radial
axonal sorting dictates lineage specification
Following HDAC1/2-Sox10-Pax3-related signaling events, SCPs
become immature SC, where the process of radial sorting takes place.
Radial sorting refers to the process by which SC choose which axons
to myelinate during development.97 It relies on the establishment of
Schwann cell polarity and cytoskeletal remodeling through Schwann
cell-axon interactions, ultimately resulting in deposition of extracellu-
lar matrix (ECM), terminal Schwann cell differentiation, and myelin
production. As expected, a variety of signals are necessary for these
processes. ECM components like Laminin 211 and 411, Collagen
XV and associated integrins α6β1, α7β1, as well as dystroglycan glyco-
sylation enzymes play a pivotal role in attachment and sorting.98–105
Intracellular signaling regulates cytoskeletal remodeling and radial
sorting through molecules such as ILK, FAK, RhoGTPases, Rac1,
Cdc42, Profilin, Merlin/NF2, and N-WASp106–112, as summarized in
Figure S2.
In addition, cell-cell communications between neurons and SC
regulate axonal myelination. Such interactions are mediated through
Neuregulin 1 (Nrg1) type III on the surface of axons and ErbB2/3 on
the surface of SC.98 Indeed inhibition of the ErbB pathway impaired
axonal sorting in zebrafish nerves,113 strongly suggesting that
ErbB2/3-Nrg1 is necessary for Schwann cell radial sorting.114–116 Fur-
thermore, the Erk/Akt signaling pathways downstream of Nrg1 were
implicated in formation of abnormal Remak bundles containing
unsorted large caliber axons, possibly through the inactivation of
Gab1 (Grb2 associated binder 1), which in turn indirectly decreases
Erk but not Akt phosphorylation.117 Finally, the Wnt/β-catenin signal-
ing has also been implicated in axonal radial sorting,118 as conditional
inactivation of β-catenin resulted in mild radial sorting defects and
impaired lamellipodia formation.119
4.3 | Metabolic signaling pathway networks in
Schwann cell development and myelination
Recent studies revealed an increasingly important role for metabolism
in neuronal and glial biology. Accumulating evidence supports the role
of key metabolic pathways in SCP development120,121; the impor-
tance of metabolic crosstalk between SC and axons122–124; and the
contributions of metabolic abnormalities to the etiology of axonal
degradation and myelin related disorders.125–129 Specifically,
mTORC1, a multiprotein complex and major integrator of several
growth factor (e.g., IGF-1) signaling pathways such as PI3K/AKT and
MAPK,130,131 drives Schwann cell proliferation or myelin production,
in a context-specific manner that depends on developmental stage.
On the one hand, mTORC1 impeded myelin production by promoting
proliferation of immature SC and inhibiting their terminal differentia-
tion and nerve development.132–134 On the other hand, myelin pro-
duction was arrested in mTOR core kinase knockout mice and
mTORC1 was identified as the cause of the deficiency due to its
prime role in lipid formation and protein biosynthesis.135 In addition,
LKB1, a serine threonine kinase upstream of AMPK, a key regulator of
cellular energetics,136–138 plays a pivotal role in myelin production and
axonal sorting in SC, with significant repercussions for PNS mye-
lination. Collectively, these studies shed light on the etiology of mye-
lopathies by providing links between metabolism and signaling during
development, thereby providing valuable insights for development of
therapeutic strategies that may involve the use of NC derived SC for
cellular therapies.139–141
5 | NCSCs: A CELL SOURCE FOR THE
TREATMENT OF DEMYELINATING
DISORDERS
Demyelinating disorders are generally defined as diseases resulting in
loss of myelin from neuronal cells with relative preservation of axons.
These disorders are a result of damage to myelin sheaths or to the cells
that produce them. Demyelinated axons tend to degenerate, resulting in
decrease or loss of neurological function. Demyelinating disorders affect
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both the CNS and PNS and can be caused by auto-immunity, certain
infectious agents, or genetic factors.142 Demyelinating diseases affecting
the CNS include in multiple sclerosis (MS), acute-disseminated encepha-
lomyelitis, acute haemorrhagic leucoencephalitis, and progressive
multifocal leukoencephalopathy, with MS being the most common dis-
abling neurological illness affecting young and middle-aged adults in
North America and Europe.143 Demyelinating diseases affecting the PNS
include the Guillain-Barré syndrome, Charcot-Marie-Tooth disease, pro-
gressive inflammatory neuropathy, and copper deficiency. These dis-
eases often result from loss of function of cells responsible for
myelination—oligodendrocytes in the CNS or SC in the PNS. Although
the causes and pathology of each of these diseases have been exten-
sively studied, the likelihood of reoccurrence is high and treatment
options are limited. Peripheral nerve injuries are also known to result in
loss ofmyelin in and around the site of injury. The incidence of peripheral
nerve injuries is fairly high, with a conservative estimates placing it
between 13 and 23 per 100,000 people per year.144 Although nerve
grafts have dominated the field of experimental treatment for peripheral
nerve injuries, their use is often limited by technical difficulties, invasive-
ness, andmediocre outcomes.145
The last few decades have seen attempts to use SC expanded in
culture for neural repair.146 SC play a central role in nerve repair—they
become activated after a nerve injury and assume a primitive pheno-
type, upregulating genes encoding for the production of neurotropic
factors and stimulating axonal regeneration. Additionally, once acti-
vated, SC produce ECM molecules such as collagen and laminin creat-
ing guided tunnels for axonal growth and regeneration.145 Various
stem cell sources have been examined for the purpose of generating
SC for the treatment of neurological diseases and peripheral nerve
injury. Here, we provide a brief review of the therapeutic potential of
these stem cells and discuss NCISC as an alternate cell source for
Schwann cell engineering.
5.1 | Stem cells for generation of autologous SC
Multipotent stem cells isolated from various adult sources may serve
as an autologous source of SC. Multipotent mesenchymal stem cells
(MSCs) have dominated this field, given their abundance and accessi-
bility via minimally invasive procedures. Adipose tissue has been
shown to be a rich source of MSCs that could be coaxed to generate
SC in vitro and myelinate axons in the spinal cord in vivo.147–152 How-
ever, these cells have limited in vitro expansion capacity, which hin-
ders their clinical usefulness. Adult neural stem cells isolated from the
brain have been shown to differentiate to S100/p75NTR positive SC
and improve axonal regeneration in mouse models of peripheral nerve
injury.153,154 However, neural tissue may not be an ideal source of
stem cells due to its limited accessibility, invasive procurement, and
frequent contamination with fibroblasts that may overpopulate the
cultures upon cell expansion in vitro.155 Moreover, the potency and
regenerative potential of neural stem cells may be affected by the
neurodegenerative disease affecting the patient, calling the effective-
ness of this cell source into question.
Since the discovery of the reprograming factors by Yamanaka
et al,156 the focus of cell engineering has drastically shifted to repro-
gramming patient-specific somatic cells to pluripotent stem cells).
These iPSCs can then be coaxed to differentiate to any cell type by
exposing them to signals that mimic embryonic development. In this
regard, iPSCs have been considered as a potentially unlimited source
of SC,157–159 which have been shown to induce axonal regrowth and
facilitate myelination in mouse models of SCI.160,161 ESCs derived
from blastocyst stage embryos can also be used to produce SC, but
significant ethical concerns are plaguing their clinical use. Clinical
cases with patients undergoing cell-based therapies for SCI have been
evaluated in detail by Harrop et al.162 Though there has been consid-
erable progress in the treatment of SCI and other neurodegenerative
diseases, there clearly is a need of more accessible and easily expand-
able adult stem cell sources for derivation of myelinating SC.
5.2 | Adult tissue–derived NCISCs for Schwann cell
therapy
NC cells give rise to SC in vivo during development, thus making them
one of the most suitable candidates as an autologous cell source of
SC. ESCs and iPSCs go through an intermediate NC fate when coaxed
to differentiate into SC, and some of these studies were discussed
previously.157 Although most studies establish differentiation of plu-
ripotent cells to mature SC, as evidenced by expression of S100β and
MBP, few have demonstrated Schwann cell function in vivo.
As discussed above, several adult human tissues can also serve as
potential sources of NCISCs. In one of the first studies, adult skin-
derived precursor cells (SKPs) were shown to have the potential to
generate SC. SKPs are multipotent cells that are present in the skin
dermis and express NC markers including Pax3, Snail, Slug, and
NGFR.28 However, SKPs do not express the key NC transcription fac-
tors, SOX10 and FOXD3, and they have not been reported to give rise
to melanocytes, chondrocytes, or osteocytes, all cells known to be
derived from NCs. More recently, lineage tracing studies showed that
murine SKPs are of mesodermal origin, in contrast to NCSC that origi-
nate from the ectoderm. Nevertheless, mesodermal SKPs gave rise to
myelinating SC in the presence of signaling cues such as heregulin β,
FGF, and forskolin, suggesting plasticity of developmentally defined
lineage boundaries163 (Table 1). Furthermore, SKP-derived SC were
shown to myelinate axons as efficiently as CNS-derived precursors,
thus establishing them as a potent cell source for the treatment of
SCI.169 Similarly, rat-derived SKP-SCs aided sensory,171 motor,175,176
and behavioral recovery,172 and enhanced peripheral nerve regenera-
tion compared with acellular nerve grafts.174,177 Finally, SC generated
from SKPs were used successfully for the treatment of incomplete
cervical SCI.170,175,178
Recently, NCISCs were isolated from the bulge of hair follicles and
coaxed to differentiate into SC, a process that required NRG1 and
micro-RNA miR-21.165 These SC expressed SOX10, p75NTR (NGFR),
KROX20, MBP, and S100β and interacted with axons in a DRG
coculture model, thus providing evidence of their functionality. Dental
pulp stem cells derived from human wisdom teeth have also been
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shown to resemble NCSC and were capable of differentiating into
S100β-expressing SC.166 Finally, human and rat bone marrow–derived
NC-like cells were also capable of differentiating into SC in vitro.11,167
Recently, our laboratory showed that cultures of KC from inter-
follicular epidermis could be the source of NClSCs (termed KC-NC),
after induction with specific chemical cues.30 KC-derived NCISCs
could be coaxed to differentiate into functional neurons, SC, melano-
cytes, osteocytes, chondrocytes, adipocytes, and smooth muscle cells
in vitro. Most notably, upon transplantation into chick embryos, KC-
NCs migrated along stereotypical pathways and gave rise to multiple
NC derivatives, providing strong support of their NC-like phenotype.
Specifically, these cells gave rise to BLBP+ glial cells in ovo and were
localized around the axon bundles. Interestingly, KC-NC from aged
donors maintained the same differentiation potential in vitro and in
ovo,32 indicating the potential of adult epidermis as a source of KC-
NC for the treatment of neurodegenerative diseases. Current studies
in our laboratory employ the hypomyelinating Shiverer/Rag2−/−
mouse—a model of congenital hypomyelinating disease that has
become the gold standard for the assessment of myelinating cell
preparations—to examine whether KC-NC or SC derived from them
can be used to myelinate axons and rescue the shiverer phenotype.
Table 1 depicts studies describing differentiation of adult tissue–
derived NClSCs to SC.
6 | CONCLUSION AND FUTURE
PERSPECTIVES
NC cells have attracted great interest due to their ability to differenti-
ate into multiple cell types.156 Although NC stem cells are a transient
cell population in developing embryos, multiple investigators have iso-
lated cells with NC-like characteristics, including transcriptional profile
and differentiation potential, from a variety of adult tissues like DRG,
bone marrow, skin, carotid body, whisker pad, heart, gut, and cranial
tissues like cornea, iris, hard palate, dental pulp, and oral mucosa.1
Regardless of source, NC-like cells have been coaxed to differentiate
into SC, neurons, chondrocytes, smooth muscle cells, and even
cardiomyocytes,2,179,180 providing a multipotent stem cell source for
the treatment of demyelinating and other neurodegenerative disor-
ders. Patient-derived NCISCs harboring mutations for neurogenic dis-
eases may also be used to study disease pathogenesis as well as
provide a platform for drug screening further increasing their clinical
potential.1
The use of SC derived from adult tissue–derived NClSCs for the
treatment of SCI has gained momentum in recent years, after demon-
stration of successful myelination of axons in vitro and in vivo.
Though these results are very promising, most studies use cells
derived from mice or rats, which are implanted in a mouse contusion
model of SCI. However, the potential of these cells for the treatment
of demyelinating disease in large animal models or humans has yet to
be established. Furthermore, most studies have focused on mye-
lination after SCI and not treatment of demyelinating disorders of the
CNS or PNS, leaving the field fairly unexplored in this domain. Finally,
isolation of NCISCs from patients suffering from neurodegenerative
disorders and their differentiation to SC and neurons may help iden-
tify abnormalities in myelin production and nerve conduction, aiding
in better disease diagnosis and development of patient-specific
therapies.
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